In our HC-NPs, we combined the specific anticancer activity of IM that binds specifically to the BCR-ABL oncoprotein present only in the CML cells, and the anticancer property of AgNPs, thanks to the production of ROS, in order to improve their efficacy on cancer cells only. Here, BCR is linked to cancer.